Gilead Sciences (NASDAQ:GILD) Given a $75.00 Price Target by Morgan Stanley Analysts

Morgan Stanley set a $75.00 target price on Gilead Sciences (NASDAQ:GILD) in a report released on Friday morning, TipRanks reports. The firm currently has a hold rating on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. Mizuho set a $81.00 target price on Gilead Sciences and gave the stock a buy rating in a research report on Tuesday, October 15th. Needham & Company LLC restated a hold rating on shares of Gilead Sciences in a research report on Monday, July 15th. Wells Fargo & Co upgraded Gilead Sciences from a market perform rating to an outperform rating and boosted their target price for the stock from $68.00 to $88.00 in a research report on Monday, July 15th. JPMorgan Chase & Co. restated a buy rating and set a $85.00 target price on shares of Gilead Sciences in a research report on Wednesday, July 31st. Finally, Raymond James dropped their target price on Gilead Sciences from $85.00 to $81.00 and set a strong-buy rating for the company in a research report on Friday. One analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $79.27.

Shares of GILD stock traded up $0.41 on Friday, reaching $63.73. 7,854,585 shares of the stock were exchanged, compared to its average volume of 6,659,807. The stock has a market cap of $83.59 billion, a PE ratio of 10.36, a P/E/G ratio of 3.00 and a beta of 1.10. Gilead Sciences has a one year low of $60.32 and a one year high of $72.90. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. The stock has a 50 day moving average price of $64.60 and a 200 day moving average price of $65.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.01. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. Gilead Sciences had a return on equity of 36.91% and a net margin of 12.04%. The firm’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.84 earnings per share. On average, research analysts expect that Gilead Sciences will post 6.68 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.95%. Gilead Sciences’s payout ratio is 40.98%.

In other news, Director Olsen Per Wold sold 4,908 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the completion of the transaction, the director now directly owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $64.35, for a total value of $39,124.80. Following the transaction, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,750,191.30. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Cooper Financial Group boosted its position in Gilead Sciences by 4.3% during the second quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 149 shares during the last quarter. LeJeune Puetz Investment Counsel LLC raised its stake in Gilead Sciences by 0.6% in the third quarter. LeJeune Puetz Investment Counsel LLC now owns 26,385 shares of the biopharmaceutical company’s stock valued at $1,672,000 after buying an additional 155 shares during the period. Alpha Cubed Investments LLC raised its stake in Gilead Sciences by 0.6% in the second quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock valued at $1,729,000 after buying an additional 156 shares during the period. Blume Capital Management Inc. raised its stake in Gilead Sciences by 4.8% in the second quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 165 shares during the period. Finally, Perigon Wealth Management LLC raised its stake in Gilead Sciences by 0.3% in the second quarter. Perigon Wealth Management LLC now owns 51,335 shares of the biopharmaceutical company’s stock valued at $3,468,000 after buying an additional 165 shares during the period. 79.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: What is the float in trading stocks?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.